Bladder cancer under staging: still unavoidable?

Angelo Naselli¹, Andrea Guarneri²

¹Urology Department, San Giuseppe Hospital, Multimedica Group, Milan, Italy; ²University Department of Urology, San Giuseppe Hospital, Multimedica Group, Milan, Italy

Correspondence to: Dr. Angelo Naselli. San Giuseppe Hospital, Via San Vittore 12, 20123 Milan, Italy. Email: angelo.naselli@auro.it.

Provenance: This is an invited article commissioned by the Section Editor Xiao Li (Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).


Submitted Aug 13, 2019. Accepted for publication Sep 22, 2019.
doi: 10.21037/tau.2019.09.44
View this article at: http://dx.doi.org/10.21037/tau.2019.09.44

Magnitude of the issue

Under staging of locally advanced bladder urothelial cancer (BUC) is an important issue as far as it impacts the treatment and may hamper eventually the prognosis. It is particularly true for cT1 BUC as far as guidelines (1) provide also conservative treatment, which is indeed unfit to treat invasive cancer, leading to an impaired chance of surviving. Overall, under staging is not a rare phenomenon. It ranges up to 25% in specimen of second transurethral resection (2) and up to 50% in specimen of radical cystectomy (1,3) without significant improvement in the last decades.

How to deal with under staging

How may we overcome the issue? Basically, there is a consensus on performing always a restaging as indicated by guidelines (TUR) (1). About 10% of cT1 BUC harbour invasive cancer after a second TUR is performed, independently from operator experience and technicalities adopted during the first procedure (2). Contrast computed tomography (CT) scan and magnetic resonance (MR) are reliable tools for the detection of nodal or distant metastasis when muscle invasive or metastatic cancer is suspected (1). Indeed, MR is gaining an increasing role in the local staging of BUC. In 2018, the VI-RADS score has been implemented (4). VI-RADS is a five-point scoring system linked to likelihood of up staging to muscle invasive disease. A validation study showed promising results. Area under the receiver operating characteristic curve was 0.94, with a 95% CI of 0.9–0.98, whereas a VI-RADS score of 3 or greater had a sensitivity of 87.1% (95% CI: 78–93%) and specificity of 96.5% (95% CI: 93–98%), respectively (5). Clinical predictive factors of up staging may be also useful. Hydronephrosis at clinical presentation or lymphovascular invasion on TUR specimen are significantly linked with upstaging (3,6) as well as variant urothelial histology (micropapillary, nested, plasmacytoid, sarcomatoid) and prostatic urethral involvement (7) and should be considered when assessing a cT1 BUC.

Molecular staging and bladder cancer

Molecular staging is a relatively new approach, based on pattern of genes expression in specimen of BUC tumours, which may be encompassed in the general concept of the precision medicine. Up to date, basically, two main subtypes of BUC have been identified, luminal and basal, the latter associated with a worse prognosis (8,9). An alternative classification, based also on cell cycle alteration and markers of differentiation, includes the subsequent subtypes: urothelial-like (luminal), genomically unstable, basal-squamous, mesenchymal-like, and neuroendocrine-like subtype with most of the tumours belonging to the first three categories (10). As a matter of fact, BUCs are characterized by a discrete heterogeneity (10). Therefore, specimen used for subtyping analyses may only express one of the patterns which compose the entire tumour. Maybe this is the reason why, so far, concerns have been raised about usefulness of molecular subtyping at the present point of our knowledge (8). Its clinical impact has been retrospectively tested in patients with BUC. Basal BUC seemed linked with a
better response to neoadjuvant chemotherapy (11) whereas no association has been found between subtyping and radiation response in a population submitted to trimodal therapy for invasive BUC (12). The study of Lotan and colleagues is original as far as they investigated the link between upstaging after radical cystectomy and molecular subtyping (13). They retrospectively reviewed a cohort of patients submitted to radical cystectomy without prior neoadjuvant therapy. Overall 206 patients with cT1–2 patients were included in their analysis. One hundred had luminal subtype cancer and 106 non luminal. Non luminal patients had a significantly higher risk of up staging to pT3–4 disease (47% versus 24%). Moreover, adding molecular subtyping to clinical staging increased the area under the curve of their predictive model from 0.67 to 0.72. Probably, those findings may be translated to the subgroup of cT1 stage patients (87 subjects had a cT1 stage BUC and 31 were up staged to pT2–4 disease), making them extremely interesting.

Conclusions

Under staging of cT1 BUC is yet a relevant issue. It may occur frequently even using the best of our knowledge. The combination of different modalities may at least reduce significantly the likelihood of under staging, which may have catastrophic consequences, due to improper allocation of the patient to the wrong treatment. Molecular subtyping as well as VI-RADS score of a dedicated MRI, if confirmed in larger, prospective cohorts, may be the missing piece of the puzzle.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References
